View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 11, 2022updated 11 Jul 2022 1:54pm

Pyramid and Caris partner to boost patient matching for solid tumour trials

Caris ’customised Molecular Intelligence Trials aids in matching the right participants to the right trials.

Pyramid Biosciences and Caris Life Sciences have entered a partnership to boost potential participant identification with NTRK fusion-driven cancers for the ongoing Phase I/II PBI-200-101 clinical trial of the former’s PBI-200.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A lead oncology programme of Pyramid, PBI-200 is a CNS-penetrant TRK inhibitor.

The multicentre, open-label, international Phase I/II trial will enrol NTRK fusion-positive advanced or metastatic tumour patients, including those with primary and metastatic CNS tumours. 

It will have a dose-escalation phase and a subsequent multicohort expansion at the recommended Phase II dose of PBI-200. 

Pyramid Bio CEO Brian Lestini said: “This collaboration will further advance the promise of precision oncology, with the potential to deliver highly differentiated compounds against validated cancer targets. 

“Caris’ patient identification and matching service is invaluable for enabling the development of novel precision therapies, especially in genetically-defined populations like NTRK.”

In preclinical studies, PBI-200 demonstrated to attain increased levels of penetration into the brain, which translated to improved efficacy in intracranial xenograft models versus other TRK inhibitors. 

It was also found to possess a favourable safety profile.

Caris focuses on the development and delivery of new solutions to transform healthcare. The customised Molecular Intelligence Trials (MI Trials) of the company aid in matching the right participants to the right trials.

The matching is made based on the molecular tumour profile of the patient and the trial’s eligibility needs.

Caris provides a growing portfolio of trials through its Right-In-Time clinical trial solution, with more than 50 therapy options available.

Furthermore, over 450 research-ready trial centres are available if a patient is detected using a Caris molecular profile outside a current sponsor study site. 

This network aids in offering trials to patients who are otherwise unable to gain access to such new treatments.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena